Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$124.72
+0.5%
$132.36
$99.06
$148.06
$7.56B0.44735,633 shs11,665 shs
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
$54.79
-0.2%
$63.90
$53.37
$93.90
$3.15B1.79840,692 shs11,691 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
+1.00%-12.58%-13.50%+0.81%+3.10%
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
+0.47%-6.11%-6.22%-17.22%-26.37%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.9132 of 5 stars
4.51.00.04.04.12.53.1
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
4.431 of 5 stars
3.31.02.51.52.74.21.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
2.93
Moderate Buy$187.7150.51% Upside
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
2.50
Moderate Buy$74.0035.06% Upside

Current Analyst Ratings Breakdown

Latest JAZZ and SMG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/10/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$200.00 ➝ $217.00
3/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$175.00 ➝ $183.00
3/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$145.00 ➝ $179.00
3/6/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$220.00 ➝ $230.00
3/5/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$210.00 ➝ $210.00
3/4/2025
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$78.00 ➝ $70.00
2/27/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$190.00 ➝ $200.00
2/26/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$140.00 ➝ $150.00
2/26/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$163.00 ➝ $176.00
2/26/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$179.00 ➝ $178.00
2/26/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $209.00
(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.07B1.86$25.40 per share4.91$59.36 per share2.10
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
$3.56B0.88$3.26 per share16.81($8.34) per share-6.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$414.83M$8.7917.526.671.0411.60%29.30%9.72%4/29/2025 (Estimated)
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
-$34.90M-$0.48N/A13.56N/A-0.67%-51.48%4.85%5/7/2025 (Estimated)

Latest JAZZ and SMG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/29/2025Q1 2025
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
-$1.23-$0.89+$0.34-$1.21$392.62 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
$2.644.82%+1.03%N/A N/A

Latest JAZZ and SMG Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2025
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
quarterly$0.663.4%2/21/20252/21/20253/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
1.46
4.26
3.74
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
N/A
1.88
0.55

Institutional Ownership

CompanyInstitutional Ownership
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
74.07%

Insider Ownership

CompanyInsider Ownership
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.20%
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
25.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
3,20060.73 million57.92 millionOptionable
The Scotts Miracle-Gro Company stock logo
SMG
Scotts Miracle-Gro
6,20057.47 million42.89 millionOptionable

Recent News About These Companies

ScottsMiracle-Gro Highlights World Water Day

New MarketBeat Followers Over Time

Media Sentiment Over Time

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$124.72 +0.57 (+0.46%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Scotts Miracle-Gro stock logo

Scotts Miracle-Gro NYSE:SMG

$54.79 -0.10 (-0.18%)
As of 09:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Scotts Miracle-Gro Company, together with its subsidiaries, manufactures, markets, and sells products for lawn, garden care, and indoor and hydroponic gardening in the United States and internationally. It operates through three segments: U.S. Consumer, Hawthorne, and Other. The company provides lawn care products, comprising lawn fertilizers, grass seed products, spreaders, and other durable products, as well as lawn-related weed, pest, and disease control products; and gardening and landscape products, which include water-soluble and continuous-release plant foods, potting mixes, garden soils, mulches and ground cover products, plant-related pest and disease control products, organic garden products, and live goods and seeding solutions. It offers hydroponic products that help users to grow plants, flowers, and vegetables using little or no soil; lighting systems and components for use in hydroponic and indoor gardening applications; insect, rodent, and weed control products for home areas; and non-selective weed killer products. The company sells its products under the Scotts, Turf Builder, EZ Seed, PatchMaster, Thick'R Lawn, GrubEx, EdgeGuard, Handy Green II, Miracle-Gro, LiquaFeed, Shake N Feed, Hyponex, Earthgro, Nature Scapes, Ortho, Miracle-Gro Performance Organics, Miracle-Gro Organic Choice, Whitney Farms, EcoScraps, Mother Earth, Botanicare, General Hydroponics, Cyco, Gavita, Agrolux, HydroLogic Purification System, Gro Pro, AeroGarden, Titan, Tomcat, Ortho Weed B Gon, Roundup, Groundclear, and Alchemist brands. It serves home centers, mass merchandisers, warehouse clubs, large hardware chains, independent hardware stores, nurseries, garden centers, e-commerce platforms, and food and drug stores, as well as indoor gardening and hydroponic distributors, retailers, and growers. The Scotts Miracle-Gro Company was founded in 1868 and is headquartered in Marysville, Ohio.